Ascletis Pharma Inc.

OTCPK:ASCL.F Stock Report

Market Cap: US$365.4m

Ascletis Pharma Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

OTCPK:ASCL.F Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
20 Nov 24BuyUS$849,527Jinzi Jason WuIndividual3,973,000US$0.21
04 Nov 24BuyUS$1,121,599Jinzi Jason WuIndividual6,043,000US$0.19

Insider Trading Volume

Insider Buying: ASCL.F insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of ASCL.F?
Owner TypeNumber of SharesOwnership Percentage
Institutions11,727,6761.21%
General Public87,612,5879.05%
Private Companies209,672,01321.7%
Individual Insiders658,906,72468.1%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 13 shareholders own 90.95% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
57.1%
Jinzi Jason Wu
552,288,164US$208.5m7.13%no data
10.9%
Yang Dan
105,463,060US$39.8m0%no data
8.56%
Lakemont Holding Llc
82,827,414US$31.3m0%no data
6.48%
Jjw11 Limited
62,689,872US$23.7m0%no data
5.24%
CBC Investment Twelve Limited
50,729,518US$19.2m0%no data
1.39%
CBC Investment Fifteen Limited
13,425,209US$5.1m0%no data
0.34%
E Fund Management Co., Ltd.
3,285,000US$1.2m0%no data
0.27%
Dimensional Fund Advisors LP
2,582,676US$975.0k-31.7%no data
0.23%
JP Morgan Asset Management
2,265,000US$855.0k0%no data
0.19%
China Universal Asset Management Company Ltd.
1,818,000US$686.3k0%no data
0.16%
Fullgoal Fund Management Co. Ltd.
1,591,000US$600.6k0%no data
0.12%
Hejingdao Wu
1,155,500US$436.2k0%no data
0.019%
American Century Investment Management Inc
186,000US$70.2k0%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/27 19:03
End of Day Share Price 2024/12/16 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Ascletis Pharma Inc. is covered by 7 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ling ZhangChina Merchants Securities (HK) Co., Ltd
Mingrui WangEverbright Securities Co. Ltd.
Siao YeEverbright Securities Co. Ltd.